Mark Heinen - Better Therapeutics Head CFO
| BTTXDelisted Stock | USD 0.73 0.04 5.19% |
Insider
Mark Heinen is Head CFO of Better Therapeutics
| Age | 55 |
| Phone | 415 887 2311 |
| Web | https://www.bettertx.com |
Mark Heinen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Heinen against Better Therapeutics otc stock is an integral part of due diligence when investing in Better Therapeutics. Mark Heinen insider activity provides valuable insight into whether Better Therapeutics is net buyers or sellers over its current business cycle. Note, Better Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Better Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Heinen over three months ago Acquisition by Mark Heinen of 8500 shares of Volato at 0.8 subject to Rule 16b-3 | ||
Mark Heinen over a year ago Acquisition by Mark Heinen of 54000 shares of Better Therapeutics subject to Rule 16b-3 |
Better Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.9505) % which means that it has lost $0.9505 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.2164) %, meaning that it created substantial loss on money invested by shareholders. Better Therapeutics' management efficiency ratios could be used to measure how well Better Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Better Therapeutics currently holds 14.88 M in liabilities with Debt to Equity (D/E) ratio of 0.81, which is about average as compared to similar companies. Better Therapeutics has a current ratio of 5.13, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Better Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Better Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Better Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Better to invest in growth at high rates of return. When we think about Better Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Deepika PharmD | Pmv Pharmaceuticals | 47 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| BSc FRCPC | Inhibikase Therapeutics | N/A | |
| MBA BS | AN2 Therapeutics | 49 | |
| Steven Ruhl | Forte Biosciences | 67 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Russell MS | Acumen Pharmaceuticals | 65 | |
| Surendra Singh | Inhibikase Therapeutics | N/A | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| MSc MBA | Inozyme Pharma | 52 | |
| Jc MD | Adagene | 59 | |
| Eugene Jiang | ABVC Biopharma | 38 | |
| Benjamin Dake | Aerovate Therapeutics | 48 | |
| Howard MD | ABVC Biopharma | 67 | |
| MA MS | Inozyme Pharma | N/A | |
| MD MBA | Rezolute | N/A | |
| Leeds Chow | ABVC Biopharma | 35 | |
| MBA MR | Aerovate Therapeutics | 62 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
Management Performance
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 |
Better Therapeutics Leadership Team
Elected by the shareholders, the Better Therapeutics' board of directors comprises two types of representatives: Better Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Better. The board's role is to monitor Better Therapeutics' management team and ensure that shareholders' interests are well served. Better Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Better Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Karbe, Interim CEO | ||
| Thiago Oliveira, Chief Officer | ||
| Angela Willis, Senior Access | ||
| Kevin Appelbaum, CoFounder Director | ||
| Jessica Meng, Chief Officer | ||
| Mark MD, Chief Officer | ||
| Mark Heinen, Head CFO | ||
| Kristin Wynholds, Chief Officer | ||
| Leslie Miller, Controller | ||
| Andres Camacho, Senior Engineering | ||
| David MBA, CoFounder Chairman | ||
| Diane GomezThinnes, Chief Officer |
Better Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Better Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.22 | ||||
| Return On Asset | -0.95 | ||||
| Current Valuation | 8.83 M | ||||
| Shares Outstanding | 54.52 M | ||||
| Shares Owned By Insiders | 53.41 % | ||||
| Shares Owned By Institutions | 2.94 % | ||||
| Number Of Shares Shorted | 2.13 M | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 49,559 X | ||||
| Gross Profit | (674 K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Better OTC Stock
If you are still planning to invest in Better Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Better Therapeutics' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |